GHRP-2 Improves Weight and Hypoglycemia in Severe Anorexia Nervosa Patient
Background
Anorexia Nervosa (AN) is a severe psychiatric disorder characterized by extreme emaciation, malnutrition, and often life-threatening complications like hypoglycemia (low blood sugar). Current treatments often struggle to restore body weight and metabolic stability in severely affected patients, leading to high morbidity and mortality. This study investigated whether growth hormone releasing peptide-2 (GHRP-2) could improve body weight and metabolic parameters in a severely emaciated AN patient.
Results
After one year of GHRP-2 treatment, the patient showed significant improvements in key health markers. The patient's body weight increased from 26.5 kg to 34.0 kg, representing a substantial gain of 7.5 kg. Furthermore, episodes of hypoglycemia (low blood sugar) were completely eliminated, indicating improved metabolic stability. The most critical finding was the 28.3% increase in body weight and the complete resolution of hypoglycemia in this severely emaciated patient over the one-year treatment period. This improvement contrasts sharply with the typical progression of severe AN, where such gains are rare without intensive inpatient care, highlighting the potential therapeutic effect of GHRP-2 in a challenging clinical scenario.
Why It Matters
This case report suggests GHRP-2 could be a novel therapeutic strategy for severe anorexia nervosa, particularly for patients struggling with extreme emaciation and metabolic instability. The ability to restore body weight and resolve hypoglycemia with an intranasal application is highly significant, potentially offering a less invasive and more accessible treatment option compared to traditional interventions. These promising results warrant further investigation into GHRP-2's efficacy and safety in larger clinical trials for anorexia nervosa. Future research should include Phase II and Phase III human trials to confirm these findings and establish optimal dosing protocols.